Trial Profile

A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LOXO-260 (Primary)
Indications Medullary thyroid cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Eli Lilly and Company

Most Recent Events

25 Oct 2024 Results (n=64, data cut-off: 11 Jan 2024) assessing the safety profile, PK and clinical activity of LOXO-260, presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics
26 Mar 2024 Planned End Date changed from 1 Apr 2026 to 1 Jun 2025.
26 Mar 2024 Planned primary completion date changed from 1 Apr 2026 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com